The Role of 5-Fluorouracil in Preventing Recurrence After Enucleation of Odontogenic Keratocyst: A Case Report

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2023 Oct 9

PMID 37809265

Authors

Chuimee Gogoi Barua

Iqbal Ali

Ashish Tripathi

Arindam Malakar

Pranjit K Singha

Affiliations

Soon will be listed here.

Abstract

The odontogenic keratocyst (OKC) is known for its high recurrence rate and disputed treatment modalities. In this report, we review the literature elucidating the efficacy of 5-fluorouracil (5-FU) topical application for recurrent OKC, and discuss the management of an OKC with 5-FU after enucleation and a 12-month follow-up. A 38-year-old female patient with an aggressive OKC in the right mandible underwent surgical curettage followed by topical application of 5-FU. Regular follow-up examinations for 12 months (radiological evaluation at three, six, and 12-month intervals) showed no signs of recurrence, with complete resolution of the cystic lesion and gradual bone regeneration. New bone formation was identified in the radiographic follow-up. This case demonstrates the potential efficacy of topical 5-FU as a promising treatment modality for OKC, warranting further research and validation. A novel and successful therapy for OKC is the topical application of 5-FU. After enucleation, topical application of 5-FU efficiently treats OKC, leading to normal bone healing and regeneration without any adverse local or systemic effects.

References

Booms P, Harth M, Sader R, Ghanaati S . Vismodegib hedgehog-signaling inhibition and treatment of basal cell carcinomas as well as keratocystic odontogenic tumors in Gorlin syndrome. Ann Maxillofac Surg. 2015; 5(1):14-9. PMC: 4555941. DOI: 10.4103/2231-0746.161049. View

Qu J, Yu F, Hong Y, Guo Y, Sun L, Li X . Underestimated PTCH1 mutation rate in sporadic keratocystic odontogenic tumors. Oral Oncol. 2014; 51(1):40-5. DOI: 10.1016/j.oraloncology.2014.09.016. View

Gonzalez-Alva P, Tanaka A, Oku Y, Yoshizawa D, Itoh S, Sakashita H . Keratocystic odontogenic tumor: a retrospective study of 183 cases. J Oral Sci. 2008; 50(2):205-12. DOI: 10.2334/josnusd.50.205. View

Geletu G, Burlacu A, Baciu E, Diaconu-Popa D, Murariu A, Foia L . Various Surgical Interventions in Treating Odontogenic Keratocyst: A Radiological Case Report. Healthcare (Basel). 2023; 11(3). PMC: 9914541. DOI: 10.3390/healthcare11030416. View

Fidele N, Yueyu Z, Zhao Y, Tianfu W, Liu J, Sun Y . Recurrence of odontogenic keratocysts and possible prognostic factors: Review of 455 patients. Med Oral Patol Oral Cir Bucal. 2019; 24(4):e491-e501. PMC: 6667002. DOI: 10.4317/medoral.22827. View

Ledderhof N, Caminiti M, Bradley G, Lam D . Topical 5-Fluorouracil is a Novel Targeted Therapy for the Keratocystic Odontogenic Tumor. J Oral Maxillofac Surg. 2016; 75(3):514-524. DOI: 10.1016/j.joms.2016.09.039. View

Salonga D, Danenberg K, Johnson M, Metzger R, Groshen S, Tsao-Wei D . Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res. 2000; 6(4):1322-7. View

Myoung H, Hong S, Hong S, Lee J, Lim C, Choung P . Odontogenic keratocyst: Review of 256 cases for recurrence and clinicopathologic parameters. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001; 91(3):328-33. DOI: 10.1067/moe.2001.113109. View

Lone P, Wani N, Ahmed Janbaz Z, Bibi M, Kour A . Topical 5-fluorouracil application in management of odontogenic keratocysts. J Oral Biol Craniofac Res. 2020; 10(4):404-406. PMC: 7394907. DOI: 10.1016/j.jobcr.2020.07.008. View

10.

Dashow J, McHugh J, Braun T, Edwards S, Helman J, Ward B . Significantly Decreased Recurrence Rates in Keratocystic Odontogenic Tumor With Simple Enucleation and Curettage Using Carnoy's Versus Modified Carnoy's Solution. J Oral Maxillofac Surg. 2015; 73(11):2132-5. DOI: 10.1016/j.joms.2015.05.005. View

11.

Philipsen H, Reichart P . Classification of odontogenic tumours. A historical review. J Oral Pathol Med. 2006; 35(9):525-9. DOI: 10.1111/j.1600-0714.2006.00470.x. View

12.

Rui Z, Li-Ying P, Jia-Fei Q, Ying-Ying H, Feng C, Tie-Jun L . Smoothened gene alterations in keratocystic odontogenic tumors. Head Face Med. 2014; 10:36. PMC: 4166020. DOI: 10.1186/1746-160X-10-36. View

13.

Sethy C, Kundu C . 5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: Implication of DNA repair inhibition. Biomed Pharmacother. 2021; 137:111285. DOI: 10.1016/j.biopha.2021.111285. View

14.

El-Naggar A, Chan J, Takata T, Grandis J, Slootweg P . The fourth edition of the head and neck World Health Organization blue book: editors' perspectives. Hum Pathol. 2017; 66:10-12. DOI: 10.1016/j.humpath.2017.05.014. View

15.

Woolgar J, Rippin J, BROWNE R . A comparative study of the clinical and histological features of recurrent and non-recurrent odontogenic keratocysts. J Oral Pathol. 1987; 16(3):124-8. DOI: 10.1111/j.1600-0714.1987.tb01478.x. View

16.

Ren C, Amm H, DeVilliers P, Wu Y, Deatherage J, Liu Z . Targeting the sonic hedgehog pathway in keratocystic odontogenic tumor. J Biol Chem. 2012; 287(32):27117-25. PMC: 3411054. DOI: 10.1074/jbc.M112.367680. View

17.

Caminiti M, El-Rabbany M, Jeon J, Bradley G . 5-Fluorouracil Is Associated With a Decreased Recurrence Risk in Odontogenic Keratocyst Management: A Retrospective Cohort Study. J Oral Maxillofac Surg. 2020; 79(4):814-821. DOI: 10.1016/j.joms.2020.07.215. View

18.

Johnston P, Drake J, Trepel J, Allegra C . Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. Cancer Res. 1992; 52(16):4306-12. View

19.

Heggie G, Sommadossi J, Cross D, Huster W, Diasio R . Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res. 1987; 47(8):2203-6. View